Author: Hughes, Dempsey L; Brunn, Jenna A; Jacobs, Jansen; Todd, Peter K; Askari, Fredrick K; Fontana, Robert J
Title: Guillain-Barré syndrome after COVID-19 mRNA vaccination in a liver transplant recipient with favorable treatment response. Cord-id: 8a1azz4q Document date: 2021_8_24
ID: 8a1azz4q
Snippet: In response to the COVID-19 global pandemic, the largest mass vaccination campaign on record was initiated. In the U.S., the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 messenger RNA (mRNA) vaccines received Emergency Use Authorization (EUA) in December 2020. Since immunosuppressed patients including liver transplant recipients (LTR) were excluded from these vaccine trials, safety and efficacy of COVID-19 vaccination in LTR are largely unknown. Herein, we report a case of acute inflammatory d
Document: In response to the COVID-19 global pandemic, the largest mass vaccination campaign on record was initiated. In the U.S., the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 messenger RNA (mRNA) vaccines received Emergency Use Authorization (EUA) in December 2020. Since immunosuppressed patients including liver transplant recipients (LTR) were excluded from these vaccine trials, safety and efficacy of COVID-19 vaccination in LTR are largely unknown. Herein, we report a case of acute inflammatory demyelinating polyneuropathy (AIDP), the most common subtype of Guillain-Barré syndrome (GBS), following initial dose of mRNA COVID-19 vaccine in an adult LTR.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date